Neoadjuvant Hepatic Arterial Infusion Chemotherapy Plus Tislelizumab Combined With Adjuvant Tislelizumab in Preventing Postoperative Recurrence for High-risk Hepatocellular Carcinoma: a Prospective, Single-arm, Phase II Clinical Study
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Jun 2024 New trial record